Most Read Articles
Stephen Padilla, Yesterday
The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Audrey Abella, 23 Jan 2019
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.

Pasireotide LAR trumps pegvisomant in reducing vertebral fracture risk in SRL-resistant acromegaly

11 Feb 2020

The risk of incident vertebral fractures (VFs) is lower among acromegaly patients with biochemically active disease treated with pasireotide LAR (Pasi) compared with those on pegvisomant (PegV), reports a recent study, which also confirms that the presence of pre-existent VFs is the main cause of incident VFs.

The investigators conducted a longitudinal retrospective international study to examine the incidence of radiological VFs in 55 patients with acromegaly who are resistant to first-generation somatostatin receptor ligands (SRL).

Twenty-three (41.8 percent) patients presented with prevalent VFs at study entry. The proportion of patients achieving biochemical acromegaly control was comparable between the two treatment groups (PegV vs Pasi: 66.7 percent vs 66.7 percent).

During follow-up, 16 patients (29.1 percent) were diagnosed with incident VFs. The occurrence of incident VFs correlated with prevalent VFs (p=0.002), persistence of active acromegaly (p=0.01) and higher value of insulin-life growth factor 1 (IGF-1) during follow-up (p=0.03).

Among patients with active disease at last visit, the occurrence of incident VFs was less frequent in those treated with Pasi compared with PegV (25 percent vs 77.8 percent; p=0.04), independently of the IGF-1 values (p=0.90). Among those who reached biochemical control, more patients in the PegV compared with the Pasi group had incident VFs (22.7 percent vs 12.5 percent; p=0.40).

Furthermore, the main determinant for incident VFs among both treatment groups was the presence of pre-existent VFs.

“Additional studies on larger populations and with longer follow-up are needed to confirm our data and disclose the mechanisms underlying our findings,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
Audrey Abella, 23 Jan 2019
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.